What is Neurocrine Biosciences's deferred tax assets?

Neurocrine Biosciences (NBIX) reported deferred tax assets of $381.4M in Q1 2026.

How has Neurocrine Biosciences's deferred tax assets changed year-over-year?

Neurocrine Biosciences's deferred tax assets decreased by 23.6% year-over-year, from $499.4M to $381.4M.

What is the long-term trend for Neurocrine Biosciences's deferred tax assets?

Over 5 years (2020 to 2025), Neurocrine Biosciences's deferred tax assets has grown at a 0.1% compound annual growth rate (CAGR), from $319.4M to $320.3M.

Non-Current Assets

Deferred Tax Assets

Neurocrine Biosciences Deferred Tax Assets increased by 19.1% to $381.4M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 23.6%, from $499.4M to $381.4M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows relatively stable performance with a 0.1% CAGR.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

First reportedQ4 2019

Last reportedQ1 2026May 5, 2026

Metric ID: non_current_assets_deferred_income_tax_assets_net

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$316.1M	$310.4M	$315.1M	$325.3M	$328.4M	$319.4M	$305.9M	$337.4M	$379M	$383.2M	$362.6M	$378.2M	$419.5M	$454.4M	$485.7M	$499.4M	$536.8M	$368.5M	$320.3M	$381.4M
QoQ Change	—	-1.8%	+1.5%	+3.2%	+1.0%	-2.7%	-4.2%	+10.3%	+12.3%	+1.1%	-5.4%	+4.3%	+10.9%	+8.3%	+6.9%	+2.8%	+7.5%	-31.4%	-13.1%	+19.1%
YoY Change	—	—	—	—	+3.9%	+2.9%	-2.9%	+3.7%	+15.4%	+20.0%	+18.5%	+12.1%	+10.7%	+18.6%	+33.9%	+32.0%	+28.0%	-18.9%	-34.1%	-23.6%

Range$305.9M – $536.8M

CAGR+4.0%

Avg YoY Growth+7.5%

Median YoY Growth+11.4%

Deferred Tax Assets at Other Companies

Bristol-Myers SquibbBMY View metric

BiogenBIIB View metric

ALN

Alnylam PharmaceuticalsALNY View metric

IncyteINCY View metric

ViatrisVTRS View metric

Johnson & JohnsonJNJ View metric

Frequently Asked Questions

What is Neurocrine Biosciences's deferred tax assets?: Neurocrine Biosciences (NBIX) reported deferred tax assets of $381.4M in Q1 2026.
How has Neurocrine Biosciences's deferred tax assets changed year-over-year?: Neurocrine Biosciences's deferred tax assets decreased by 23.6% year-over-year, from $499.4M to $381.4M.
What is the long-term trend for Neurocrine Biosciences's deferred tax assets?: Over 5 years (2020 to 2025), Neurocrine Biosciences's deferred tax assets has grown at a 0.1% compound annual growth rate (CAGR), from $319.4M to $320.3M.